Particle.news
Download on the App Store
4 ARTICLES
·
last mo.

Trump Administration Prepares Tariffs of Up to 100% for Drugmakers Without U.S. Pricing Deals

The plan invokes a national-security trade law to pressure drugmakers into U.S. price guarantees.

A general view of the White House, in Washington, D.C., U.S., July 20, 2025. REUTERS/Al Drago
President Donald Trump speaks in the Oval Office on March 3.
Image
Image

Overview

  • The administration is preparing to penalize companies that lack pricing agreements with the White House, according to Bloomberg.
  • The levy would apply to imported branded and patented medicines and could reach 100%.
  • Pfizer and AstraZeneca have secured multi-year exemptions by committing to prices through the TrumpRx.gov platform.
  • Eli Lilly, Johnson & Johnson, and Merck have pledged new U.S. investments to avoid penalties.
  • The effort sits under a Section 232 trade case and remains in flux with possible carve-outs for some medicines, following a broader 2025 drug tariff plan the Supreme Court curtailed.